Total Raised

$3.19M

Investors Count

2

Healcloud Funding, Healcloud Valuation & Healcloud Revenue

5 Fundings

Healcloud's latest funding round was a Series A for $0.09M on December 20, 2019.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

12/20/2019

Series A

$0.09M

0

FY undefined

1

1/29/2018

Seed

$99M

0

FY undefined

10

2/17/2017

Grant

$99M

0

FY undefined

10

3/21/2016

Private Equity

$99M

0

FY undefined

10

12/1/2015

Angel

$99M

0

FY undefined

10

Date

12/20/2019

1/29/2018

2/17/2017

3/21/2016

12/1/2015

Round

Series A

Seed

Grant

Private Equity

Angel

Amount

$0.09M

$99M

$99M

$99M

$99M

Investors

Valuation

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

10

10

10

10

Healcloud Investors

2 Investors

Healcloud has 2 investors. Hiventures invested in Healcloud's Seed funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

1/29/2018

12/20/2019

2
Series A, Seed (2018)

Venture Capital

Hungary

00/00/0000

00/00/0000

Hungarian Government

Subscribe to see more

Government

Hungary

First funding

1/29/2018

00/00/0000

Last Funding

12/20/2019

00/00/0000

Investor

Hungarian Government

Rounds

2
Series A, Seed (2018)

Subscribe to see more

Board Seats

Type

Venture Capital

Government

Location

Hungary

Hungary

You May Also Like

Deep 6 AI Logo
Deep 6 AI

Deep 6 AI finds patients for clinical trials in minutes rather than months. Using artificial intelligence and natural language processing on clinical data, Deep 6 AI's software accelerates patient recruitment exponentially, getting life-saving treatment to patients more quickly.

Deep Lens Logo
Deep Lens

Deep Lens is an AI company focused on identifying patients for clinical trials using VIPER, an AI-driven, digital pathology cloud platform which for over ten years has allowed pathology groups to collaborate on groundbreaking cancer research across dozens of cancer types.

Inato Logo
Inato

Inato provides an AI-based data collection tool for the pharmaceutical sector. The tool collects and analyses data for site selection and patient recruitment in clinical trials, helping to accelerate the process and reduce development costs.

Reify Health Logo
Reify Health

Reify Health provides cloud-based software that accelerates the development of new and life-saving therapies. Reify Health aims to change how clinical trials are run through its StudyTeam and Care Access platforms. StudyTeam delivers a technology platform for optimizing patient recruitment and enrollment. Care Access, which conducts decentralized trials at scale, is a decentralized research organization that aims to bring clinical trial infrastructure directly to patients, healthcare providers, and communities. Reify Health was founded in 2012 and is based in Boston, Massachusetts.

Belong.Life Logo
Belong.Life

Belong.Life develops social and professional networks for managing and navigating treatments. The company's mission is to improve the quality of life and quality of care around the world through technology, engagement, data, and AI.

TrialJectory Logo
TrialJectory

Trialjectory is an AI-based trial matching platform that uses self-reported clinical information to facilitate clinical trial search, matching, and enrollment by cancer patients and their physicians.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.